Literature DB >> 14684596

Mesalazine is safe for the treatment of IBD.

G D'Haens, A A van Bodegraven.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14684596      PMCID： PMC1773944          DOI： 10.1136/gut.53.1.155

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  7 in total

Review 1.  Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease.

Authors:  G Corrigan; P E Stevens
Journal:  Aliment Pharmacol Ther       Date:  2000-01       Impact factor: 8.171

2.  Treatment of ulcerative colitis with oral 5-aminosalicyclic acid in patients unable to take sulphasalazine.

Authors:  M J Dew; A D Harries; B K Evans; J Rhodes
Journal:  Lancet       Date:  1983-10-01       Impact factor: 79.321

3.  Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype.

Authors:  K M Das; M A Eastwood; J P McManus; W Sircus
Journal:  N Engl J Med       Date:  1973-09-06       Impact factor: 91.245

4.  Mesalazine-associated interstitial nephritis.

Authors:  M J World; P E Stevens; M A Ashton; D J Rainford
Journal:  Nephrol Dial Transplant       Date:  1996-04       Impact factor: 5.992

Review 5.  Adverse events in patients treated with 5-aminosalicyclic acid: 1993-1994 pharmacovigilance report for Pentasa in France.

Authors:  P Marteau; F Nelet; M Le Lu; C Devaux
Journal:  Aliment Pharmacol Ther       Date:  1996-12       Impact factor: 8.171

6.  Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine.

Authors:  S S Rao; P A Cann; C D Holdsworth
Journal:  Scand J Gastroenterol       Date:  1987-04       Impact factor: 2.423

7.  Mesalazine tolerance in patients with inflammatory bowel disease and previous intolerance or allergy to sulphasalazine or sulphonamides.

Authors:  U Turunen; I Elomaa; V J Anttila; K Seppälä
Journal:  Scand J Gastroenterol       Date:  1987-09       Impact factor: 2.423
  7 in total
  3 in total

Review 1.  Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?

Authors:  A A van Bodegraven; Chris J J Mulder
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

Review 2.  Five-aminosalicylic Acid: an update for the reappraisal of an old drug.

Authors:  Cristiana Perrotta; Paolo Pellegrino; Eliana Moroni; Clara De Palma; Davide Cervia; Piergiorgio Danelli; Emilio Clementi
Journal:  Gastroenterol Res Pract       Date:  2015-01-21       Impact factor: 2.260

Review 3.  Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis.

Authors:  Stephan Karl Böhm; Wolfgang Kruis
Journal:  Clin Exp Gastroenterol       Date:  2014-09-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.